Video

Freda: Managing Aggressive Treatment

Related Videos
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Image of woman with blonde hair.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
a man and a woman in front of a dark blue background
a man and a woman in front of a dark blue background
Related Content
Illustration of woman with blonde hair.
March 13th 2025

Trusting My Stage 4 Breast Cancer Body

Martha Carlson
Practicing consistency has made a difference for me while living with stage 4 breast cancer.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of woman with pink robbon.
March 11th 2025

Vepdegestrant May Reduce Disease Progression in Breast Cancer Subset

Spencer Feldman
Vepdegestrant improved progression-free survival in patients with estrogen receptor 1 mutations in advanced ER-positive, HER2-negative breast cancer.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
green background with white text indicating FDA Approval, What You Need to Know
March 8th 2025

FDA Approves Biosimilars for Cancer-Related Skeletal Events

Alex Biese
The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.
Image of woman holding her chest.
March 7th 2025

BRCA1/2 Mutations May Associate With Better Chemo Response in TNBC

Alex Biese
Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in patients with BRCA1/2 mutations.